Literature DB >> 7738668

Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.

V J Lowe1, D M DeLong, J M Hoffman, R E Coleman.   

Abstract

UNLABELLED: FDG-PET can differentiate benign from malignant focal pulmonary opacities. We performed dynamic FDG-PET studies to determine the optimum time for emission data acquisition.
METHODS: Patients with focal pulmonary abnormalities demonstrated by biopsy to be malignant (n = 10) or benign (n = 4) were evaluated with dynamic FDG-PET. Dynamic PET data were acquired as sequential 5-min images for 2.5 hr. Radioactivity concentration measurements of the focal abnormality, a similar area in the opposite lung, and both lungs in the field of view were made throughout the period of acquisition. Standardized uptake ratios (SUR) of the lesions were calculated. SUR data and lesion-to-background ratios were plotted. The time that the SUR provided the maximum separation between benign and malignant masses after FDG administration was determined.
RESULTS: The SUR values provided the greatest separation between benign and malignant abnormalities beginning at 50 min and no advantage was identified in imaging later. Achievement of a 4:1 lesion-to-background ratio occurred by 50 min in malignant lesions.
CONCLUSION: The acquisition of the emission data used in the evaluation of pulmonary malignancy should begin approximately 50 min after FDG administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738668

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  24 in total

1.  Dual-phase FDG-PET: delayed acquisition improves hepatic detectability of pathological uptake.

Authors:  V Arena; A Skanjeti; R Casoni; A Douroukas; E Pelosi
Journal:  Radiol Med       Date:  2008-07-10       Impact factor: 3.469

2.  PET imaging in pediatric neuroradiology: current and future applications.

Authors:  Sunhee Kim; Noriko Salamon; Hollie A Jackson; Stefan Blüml; Ashok Panigrahy
Journal:  Pediatr Radiol       Date:  2009-11-24

3.  Targeted imaging of cancer by fluorocoxib C, a near-infrared cyclooxygenase-2 probe.

Authors:  Md Jashim Uddin; Brenda C Crews; Kebreab Ghebreselasie; Cristina K Daniel; Philip J Kingsley; Shu Xu; Lawrence J Marnett
Journal:  J Biomed Opt       Date:  2015-05       Impact factor: 3.170

4.  Dynamic 11C-methionine PET analysis has an additional value for differentiating malignant tumors from granulomas: an experimental study using small animal PET.

Authors:  Songji Zhao; Yuji Kuge; Min Yi; Yan Zhao; Toshiyuki Hatano; Keiichi Magota; Ken-ichi Nishijima; Masashi Kohanawa; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

Review 5.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

6.  Dynamic changes of FDG uptake and clearance in normal tissues.

Authors:  Gang Cheng; Abass Alavi; Esther Lim; Thomas J Werner; Catherine V Del Bello; Scott R Akers
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

Review 7.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

8.  Usefulness of additional delayed regional F-18 Fluorodeoxy-Glucose Positron Emission Tomography in the lymph node staging of Non-Small Cell Lung Cancer patients.

Authors:  Young So; June-Key Chung; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

9.  Partial volume correction strategies for quantitative FDG PET in oncology.

Authors:  Nikie J Hoetjes; Floris H P van Velden; Otto S Hoekstra; Corneline J Hoekstra; Nanda C Krak; Adriaan A Lammertsma; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

10.  Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings.

Authors:  Virendra Kumar; Kavindra Nath; Claudia G Berman; Jongphil Kim; Tawee Tanvetyanon; Alberto A Chiappori; Robert A Gatenby; Robert J Gillies; Edward A Eikman
Journal:  Clin Nucl Med       Date:  2013-03       Impact factor: 7.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.